Open AccessS109: ACTIVATION OF PYRUVATE KINASE‐R WITH ETAVOPIVAT (FT‐4202) IS WELL TOLERATED, IMPROVES ANEMIA, AND DECREASES INTRAVASCULAR HEMOLYSIS IN PATIENTS WITH SICKLE CELL DISEASE TREATED FOR UP TO 12 WEEKS
Author(s) -
Telen M,
Saraf S,
Cruz K,
Idowu M,
Kalfa T,
Osunkwo I,
Hagar R,
Geib J,
Forsyth S,
Schroeder P,
Wu E,
Kelly P,
Brown R
Publication year - 2022
Publication title -
hemasphere
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.677
H-Index - 11
ISSN - 2572-9241
DOI - 10.1097/01.hs9.0000821404.03661.11
Subject(s) - medicine , anemia , placebo , cohort , thalassemia , gastroenterology , pathology , alternative medicine